= Facilitating University-Industry Collaboration =
There are no university collaborations that involve industrial matters at this timeXavier University has active collaboration with pharmaceutical and biotechnology industry. Dr. Tarun Mandal (College of Pharmacy) and his research team have developed an inhalable formulation of a proprietary (Tulane University and Autoimmune Technology; Flufirvite-3®) peptide for the treatment of influenza. The project is a $3.2 M NIH/NIAID grant and Dr. Mandal is the PI of the formulation core. He has successfully transferred the technology to Cirrus Pharmaceuticals for further development. He has co-authored the CMC documents supporting the IND (#101759) application. The Phase I first-in-human clinical trial of the API has been completed (#NCT01313962) last year and the Phase I clinical trial of the newly developed powder formulation will initiate soon.
= Engaging with Regional and Local Development Efforts =